Implantation and long-term assessment of the stability and biocompatibility of a novel 98 channel suprachoroidal visual prosthesis in sheep
Metadata
Show full item recordType
ArticleAuthor/s
Eggenberger, Samuel ChristianJames, Natalie L.
Ho, Cherry
Eamegdool, Steven S.
Tatarinoff, Veronika
Craig, Naomi A.
Gow, Barry S.
Wan, Susan
Dodds, Christopher W. D.
La Hood, Donna
Gilmour, Aaron
Donahoe, Shannon L.
Krockenberger, Mark
Tumuluri, Krishna
da Cruz, Melville J.
Grigg, John R.
McCluskey, Peter
Lovell, Nigel H.
Madigan, Michele C.
Fung, Adrian T.
Suaning, Gregg J.
Abstract
Severe visual impairment can result from retinal degenerative diseases such as retinitis pigmentosa, which lead to photoreceptor cell death. These pathologies result in extensive neural and glial remodelling, with survival of excitable retinal neurons that can be electrically ...
See moreSevere visual impairment can result from retinal degenerative diseases such as retinitis pigmentosa, which lead to photoreceptor cell death. These pathologies result in extensive neural and glial remodelling, with survival of excitable retinal neurons that can be electrically stimulated to elicit visual percepts and restore a form of useful vision. The Phoenix99 Bionic Eye is a fully implantable visual prosthesis, designed to stimulate the retina from the suprachoroidal space. In the current study, nine passive devices were implanted in an ovine model from two days to three months. The impact of the intervention and implant stability were assessed using indirect ophthalmoscopy, infrared imaging, and optical coherence tomography to establish the safety profile of the surgery and the device. The biocompatibility of the device was evaluated using histopathological analysis of the tissue surrounding the electrode array, with a focus on the health of the retinal cells required to convey signals to the brain. Appropriate stability of the electrode array was demonstrated, and histological analysis shows that the fibrotic and inflammatory response to the array was mild. Promising evidence of the safety and potential of the Phoenix99 Bionic Eye to restore a sense of vision to the severely visually impaired was obtained.
See less
See moreSevere visual impairment can result from retinal degenerative diseases such as retinitis pigmentosa, which lead to photoreceptor cell death. These pathologies result in extensive neural and glial remodelling, with survival of excitable retinal neurons that can be electrically stimulated to elicit visual percepts and restore a form of useful vision. The Phoenix99 Bionic Eye is a fully implantable visual prosthesis, designed to stimulate the retina from the suprachoroidal space. In the current study, nine passive devices were implanted in an ovine model from two days to three months. The impact of the intervention and implant stability were assessed using indirect ophthalmoscopy, infrared imaging, and optical coherence tomography to establish the safety profile of the surgery and the device. The biocompatibility of the device was evaluated using histopathological analysis of the tissue surrounding the electrode array, with a focus on the health of the retinal cells required to convey signals to the brain. Appropriate stability of the electrode array was demonstrated, and histological analysis shows that the fibrotic and inflammatory response to the array was mild. Promising evidence of the safety and potential of the Phoenix99 Bionic Eye to restore a sense of vision to the severely visually impaired was obtained.
See less
Date
2021Source title
BiomaterialsVolume
279Publisher
ElsevierFunding information
ARC Special Research Initiative (SRI) in Bionic Vision Science and Technology grant to Bionic Vision Australia (BVA) (2010-2015)NHMRC APP1109056
NHMRC APP1087224
Licence
Creative Commons Attribution 4.0Faculty/School
Faculty of Engineering, School of Biomedical EngineeringDepartment, Discipline or Centre
sydneyBIONICSShare